RPG Life Sciences Ltd

₹ 2,657 8.34%

09 Jul - close price

rpglifesciences.com BSE: 532983 NSE: RPGLIFE

About

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients^[1]

Key Points

Business Overview:^[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs

Website BSE NSE

Market Cap ₹ 4,383 Cr.
Current Price ₹ 2,657
High / Low ₹ 2,715 / 1,731
Stock P/E 40.0
Book Value ₹ 366
Dividend Yield 0.90 %
ROCE 25.7 %
ROE 19.3 %
Face Value ₹ 8.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 28.8%

Cons

Stock is trading at 7.26 times its book value
Debtor days have increased from 46.5 to 60.2 days.
Working capital days have increased from 44.6 days to 63.7 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	118	148	154	154	127	165	172	173	143	169	182	180	177
	103	116	116	116	106	126	126	124	118	133	143	140	144
Operating Profit	16	32	37	38	21	39	46	49	25	35	39	40	33
OPM %	13%	22%	24%	25%	16%	24%	27%	28%	18%	21%	21%	22%	19%
	2	2	2	2	2	2	-25	3	115	5	16	-5	13
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	4	4	4	4	4	5	5	5	5	5	5	5	6
Profit before tax	14	30	35	36	18	36	15	47	135	35	49	29	40
Tax %	25%	26%	26%	26%	25%	26%	72%	26%	13%	26%	25%	24%	26%
	10	22	26	26	13	27	4	35	117	26	37	22	30
EPS in Rs	6.26	13.36	15.64	16.00	8.01	16.18	2.54	21.12	70.95	15.90	22.28	13.38	18.08
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	242	279	294	344	330	376	389	440	513	582	653	708
	228	256	274	306	296	315	318	353	408	453	493	560
Operating Profit	14	23	20	38	34	60	71	87	104	129	161	148
OPM %	6%	8%	7%	11%	10%	16%	18%	20%	20%	22%	25%	21%
	1	1	18	1	1	-5	1	3	4	7	95	29
Interest	3	2	4	5	5	3	2	1	1	1	2	2
Depreciation	11	10	11	14	15	16	16	16	16	17	21	21
Profit before tax	1	12	23	20	15	36	54	73	92	118	233	154
Tax %	0%	0%	10%	34%	28%	20%	25%	30%	26%	26%	21%	25%
	1	12	21	13	11	29	40	51	68	88	183	115
EPS in Rs	0.60	7.03	12.70	8.13	6.54	17.54	24.19	31.13	40.90	53.00	110.79	69.64
Dividend Payout %	132%	23%	22%	30%	37%	23%	30%	31%	29%	30%	22%	34%

Compounded Sales Growth
10 Years:	10%
5 Years:	13%
3 Years:	11%
TTM:	8%

Compounded Profit Growth
10 Years:	25%
5 Years:	22%
3 Years:	17%
TTM:	-5%

Stock Price CAGR
10 Years:	25%
5 Years:	42%
3 Years:	42%
1 Year:	5%

Return on Equity
10 Years:	20%
5 Years:	23%
3 Years:	23%
Last Year:	19%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	112	120	134	142	147	163	203	243	294	362	517	592
	33	23	45	54	36	12	2	1	0	0	0	20
	39	49	55	82	54	78	85	88	112	138	127	168
Total Liabilities	197	205	247	291	251	267	303	345	419	513	658	793
	105	109	137	131	128	123	113	104	124	114	172	197
CWIP	1	2	2	9	17	10	12	31	25	96	16	23
Investments	0	0	0	0	0	0	0	0	58	91	127	120
	92	94	108	152	106	134	178	210	211	212	343	454
Total Assets	197	205	247	291	251	267	303	345	419	513	658	793

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-2	33	7	15	46	50	58	65	91	94	78	56
	-10	-15	-30	-16	-19	-11	-8	-35	-106	-79	-42	51
	12	-18	23	0	-26	-39	-10	-14	-17	-20	-27	-21
Net Cash Flow	-0	-0	1	-1	0	0	40	17	-32	-5	9	87
Free Cash Flow	-12	18	-48	-1	26	39	50	41	58	25	151	-9
CFO/OP	14%	150%	58%	48%	144%	94%	94%	96%	111%	96%	81%	63%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	61	48	49	72	43	62	54	27	27	31	48	60
Inventory Days	149	156	163	171	136	133	162	214	203	200	159	179
Days Payable	109	135	102	165	83	127	132	117	138	140	135	141
Cash Conversion Cycle	101	70	110	78	96	68	84	124	91	90	72	99
Working Capital Days	27	26	20	22	20	41	52	47	33	25	45	64
ROCE %	2%	9%	10%	13%	10%	23%	27%	31%	33%	35%	33%	26%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

API Revenue Share
% of total revenue

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
			x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
			x				xx	xx	xx	xx
							xx.xx	xx.xx	xx.xx	xx.xx
							xx,xxx	xx,xxx	xxx,xxx	xxx,xxx
									xx.xx
x.xx	x.xx	x.xx	x.xx			x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Domestic Formulations Revenue Share
% of total revenue

International Formulations Revenue Share
% of total revenue

Sales Force Productivity (PCPM - Overall)
INR Lakhs per rep per month

New Product Contribution (DF sales from launches since FY19)
% of DF sales

DF Growth vs IPM Market Growth
% YoY growth

Doctors Enrolled on RPG Serv Platform
Number of doctors

Specialty Sales Force Productivity (PCPM)
INR Lakhs per rep per month

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	72.82%	72.82%	72.82%	72.82%	72.82%	72.82%	72.95%	72.95%	72.95%	72.95%	72.95%	72.95%
	0.33%	0.46%	0.56%	0.90%	1.15%	1.35%	1.30%	1.46%	1.35%	1.11%	1.00%	0.87%
	0.27%	1.57%	1.77%	2.16%	2.61%	5.45%	6.06%	6.14%	6.49%	6.70%	7.04%	7.45%
	26.58%	25.15%	24.85%	24.12%	23.44%	20.40%	19.70%	19.46%	19.22%	19.23%	19.01%	18.72%
No. of Shareholders	20,226	21,088	21,866	22,137	22,232	23,481	24,891	24,867	25,832	26,657	25,905	25,282

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	67.48%	69.22%	70.99%	72.07%	72.07%	72.07%	72.82%	72.82%	72.95%	72.95%
	0.08%	0.02%	0.00%	0.01%	0.01%	0.12%	0.38%	0.90%	1.46%	0.87%
	0.25%	0.52%	0.27%	0.37%	0.03%	0.01%	0.11%	2.16%	6.14%	7.45%
	32.18%	30.24%	28.74%	27.55%	27.89%	27.80%	26.70%	24.12%	19.46%	18.72%
No. of Shareholders	16,794	15,207	15,649	15,942	18,701	22,821	20,837	22,137	24,867	25,282

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

May 2026

Transcript
PPT REC
Apr 2026

Transcript

AI Summary
PPT
Jan 2026

Transcript

AI Summary
PPT
Oct 2025
Transcript PPT REC
Jul 2025

Transcript

AI Summary
PPT
Jun 2025

Transcript

AI Summary
PPT
Apr 2025
Transcript PPT REC
Nov 2024

Transcript

AI Summary
PPT
Sep 2024
Transcript
PPT
REC
Jul 2024

Transcript

AI Summary
PPT
Jun 2024

Transcript

AI Summary
PPT
May 2024
Transcript PPT
Feb 2024

Transcript

AI Summary
PPT
Oct 2023
Transcript PPT
Jul 2023

Transcript

AI Summary
PPT
Jun 2023

Transcript

AI Summary
PPT
May 2023
Transcript PPT
Feb 2023

Transcript

AI Summary
PPT
Feb 2023

Transcript

AI Summary
PPT
Oct 2022
Transcript PPT
Sep 2022

Transcript

AI Summary
PPT
Aug 2022

Transcript

AI Summary
PPT
May 2022
Transcript PPT
Feb 2022

Transcript

AI Summary
PPT
Jan 2022

Transcript

AI Summary
PPT
Nov 2021
Transcript PPT
Aug 2021

Transcript

AI Summary
PPT
Jun 2021

Transcript

AI Summary
PPT
Jun 2019

Transcript

AI Summary
PPT
Jun 2018

Transcript

AI Summary
PPT
Nov 2017

Transcript

AI Summary
PPT
Jun 2017

Transcript

AI Summary
PPT
Nov 2016

Transcript

AI Summary
PPT
Jun 2016

Transcript

AI Summary
PPT